Clincosm LogoSign in Get a demo

Assessing Ocular Surface Changes After Changing Glaucoma Medications

Sponsor
University of Colorado, Denver (Other)
Overall Status
Completed
CT.gov ID
NCT00554411
Collaborator
(none)
22
Enrollment
1
Location
45
Duration (Months)
0.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Hypothesis: Changing to Travatan Z therapy increases the tear film break up time of subjects on Xalatan therapy presenting with ocular surface disease.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Patients who have been taking Xalatan monotherapy to treat their glaucoma and presenting with ocular surface disease will be advised to switch their medication to Travatan Z. Test results will be recorded at the day that the medication was changed and at follow-up to determine if there is a measurable change in tear film break up, corneal staining and in the Ocular Surface Disease Index.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    22 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Assessing Changes at the Ocular Surface Following the Switch From Xalatan to Travatan Z.
    Study Start Date :
    Nov 1, 2007
    Actual Primary Completion Date :
    Aug 1, 2011
    Actual Study Completion Date :
    Aug 1, 2011

    Outcome Measures

    Primary Outcome Measures

    1. Change in Signs and Symptoms of Ocular Surface Disease [6 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • on Xalatan monotherapy from 1 to 18 months

    • 18 years of age or older

    • has been diagnosed with ocular surface disease

    Exclusion Criteria:
    • special populations such as children, pregnant females, prisoners, etc.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Rocky Mountain Lions Eye Institute Aurora Colorado United States 80045-0510

    Sponsors and Collaborators

    • University of Colorado, Denver

    Investigators

    • Principal Investigator: Malik Y Kahook, M.D., Rocky mountain Lions Eye Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Colorado, Denver
    ClinicalTrials.gov Identifier:
    NCT00554411
    Other Study ID Numbers:
    • 07-0757
    First Posted:
    Nov 6, 2007
    Last Update Posted:
    Jan 27, 2017
    Last Verified:
    Jan 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by University of Colorado, Denver
    Travatan Z
    glaucoma
    tear film break up time
    Additional relevant MeSH terms:
    Glaucoma

    Study Results

    No Results Posted as of Jan 27, 2017